|
|
Volumn 28, Issue 4, 2010, Pages 295-297
|
|
Safety signal dampens reception for mipomersen antisense
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AGANIRSEN;
ALICAFORSEN;
ANTISENSE OLIGODEOXYNUCLEOTIDE;
ATORVASTATIN;
CUSTIRSEN;
FOMIVIRSEN;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
HYPOCHOLESTEROLEMIC AGENT;
LIVER ENZYME;
LUCANIX;
MIPOMERSEN;
OBLIMERSEN;
TRABEDERSEN;
UNCLASSIFIED DRUG;
ANTISENSE THERAPY;
ASTHMA;
ASTROCYTOMA;
CHRONIC LYMPHATIC LEUKEMIA;
CORONARY ARTERY DISEASE;
CROHN DISEASE;
DRUG APPROVAL;
DRUG DELIVERY SYSTEM;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG SAFETY;
ENTERITIS;
FAMILIAL HYPERCHOLESTEROLEMIA;
GLIOBLASTOMA;
GRAFT REJECTION;
HUMAN;
HYPERCHOLESTEROLEMIA;
ILEITIS;
LIVER TOXICITY;
LUNG TUMOR;
MAXIMUM TOLERATED DOSE;
MELANOMA;
NONHUMAN;
NOTE;
PRIORITY JOURNAL;
PROSTATE CANCER;
RETINITIS;
SIDE EFFECT;
SOLID TUMOR;
ULCERATIVE COLITIS;
ANTICHOLESTEREMIC AGENTS;
CLINICAL TRIALS AS TOPIC;
DRUG APPROVAL;
HUMANS;
OLIGONUCLEOTIDES;
UNITED STATES;
|
|
EID: 77950668678
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0410-295 Document Type: Note |
|
Times cited : (27)
|
|
References (0)
|
